Inderm (Erythromycin)

Erythromycin in Inderm binds to the 50S ribosomal subunit of susceptible bacteria, blocking protein synthesis. This inhibition stops bacterial growth, allowing the body’s immune system to eliminate the infection and reduce associated skin inflammation.

The dosage of Inderm is determined by the prescribing healthcare professional based on the severity of the skin condition, patient age, and treatment response. Patients should follow the prescriber’s instructions and the product label for application frequency and duration.

Inderm is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Caution is advised during breastfeeding, and a healthcare provider should be consulted.

To order Inderm, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Inderm (erythromycin) belongs to the macrolide class, offering a broad spectrum against Gram‑positive bacteria and some atypicals. Compared with topical clindamycin, erythromycin has a lower risk of resistance when used alone but may be combined for synergistic effect. Choice depends on bacterial profile, patient tolerance and prescriber preference.

Inderm should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Inderm is applied topically to the affected skin area. Clean and dry the skin before use, then spread a thin layer of the product over the lesion(s) as directed by the prescriber, usually once or twice daily. Hands should be washed after application.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and significant photosensitivity. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, blistering, or signs of systemic allergy.

Inderm should not be used by individuals with a known hypersensitivity to erythromycin, other macrolide antibiotics, or any component of the formulation. It is also contraindicated on extensive broken skin where systemic absorption could be significant, unless specifically directed by a healthcare professional.